Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer

Deepak, K.G.K.; Vempati, Rahul Kumar; Nagaraju, Ganji Purnachandra; Dasari, Venkata Ramesh; Nagini, Siddavaram; Rao, D.N.; Malla, Rama Rao

doi:10.1016/j.phrs.2020.104683

Cited by 392 publications

(286 citation statements)

References 231 publications

Supporting

Mentioning

284

Contrasting

Unclassified

Order By: Relevance

“…Compared with NFs, CAFs have the characteristics of excessive proliferation and unique cytokines. This not only induces the formation of new blood vessels, but also promotes the entry of immune cells into TME, which greatly changes the physiological function of ECM to support tumor proliferation, metastasis and treatment resistance [116,117]. However, cells involved in ECM formation are not only fibroblasts, but also chondrocytes, osteoblasts, and certain epithelial cells.…”

Section: Reshaping Ecm To Promote Tumor Progressionmentioning

confidence: 99%

Exosomal miRNAs in tumor microenvironment

Tan

Xia

et al. 2020

J Exp Clin Cancer Res

138

117

View full text Add to dashboard Cite

Tumor microenvironment (TME) is the internal environment in which tumor cells survive, consisting of tumor cells, fibroblasts, endothelial cells, and immune cells, as well as non-cellular components, such as exosomes and cytokines. Exosomes are tiny extracellular vesicles (40-160nm) containing active substances, such as proteins, lipids and nucleic acids. Exosomes carry biologically active miRNAs to shuttle between tumor cells and TME, thereby affecting tumor development. Tumor-derived exosomal miRNAs induce matrix reprogramming in TME, creating a microenvironment that is conducive to tumor growth, metastasis, immune escape and chemotherapy resistance. In this review, we updated the role of exosomal miRNAs in the process of TME reshaping.

show abstract

Section: Reshaping Ecm To Promote Tumor Progressionmentioning

confidence: 99%

Exosomal miRNAs in tumor microenvironment

Tan

Xia

et al. 2020

J Exp Clin Cancer Res

138

117

View full text Add to dashboard Cite

show abstract

“…The tumor microenvironment (TME) is associated with immune suppression, escape from immune detection and development of drug resistance, and is being increasingly recognized as a potential target for treatment of TNBC [63]. Tumor associated macrophages (TAMs) promote the progression and metastasis of TNBC by releasing inhibitory cytokines, reducing functions of tumor infiltrating lymphocytes (TILs), promoting T REG (regulatory T-cells), and modulating PD-1/PD-L1 expression in TME [64].…”

Section: Tme Targeting For Neoadjuvant Treatmentmentioning

confidence: 99%

Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges

Lee

Yost

Yuan

2020

Cancers

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) is an aggressive breast cancer with historically poor outcomes, primarily due to the lack of effective targeted therapies. The tumor molecular heterogeneity of TNBC has been well recognized, yet molecular subtype driven therapy remains lacking. While neoadjuvant anthracycline and taxane-based chemotherapy remains the standard of care for early stage TNBC, the optimal chemotherapy regimen is debatable. The addition of carboplatin to anthracycline, cyclophosphamide, and taxane (ACT) regimen is associated with improved complete pathologic response (pCR). Immune checkpoint inhibitor (ICI) combinations significantly increase pCR in TNBC. Increased tumor infiltrating lymphocyte (TILs) or the presence of DNA repair deficiency (DRD) mutation is associated with increased pCR. Other targets, such as poly-ADP-ribosyl polymerase inhibitors (PARPi) and Phosphatidylinositol-3-kinase/Protein Kinase B/mammalian target of rapamycin (PI3K-AKT-mTOR) pathway inhibitors, are being evaluated in the neoadjuvant setting. This review examines recent progress in neoadjuvant therapy of TNBC, including platinum, ICI, PARPi, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) pathway targeted therapies, and novel tumor microenvironment (TME) targeted therapy, in addition to biomarkers for the prediction of pCR.

show abstract

“…Triple-negative breast cancer (TNBC) refers to cancer that is negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2(HER2) and is the most aggressive subtype of breast cancer with the worst prognosis. In addition, there is also no clinically applicable therapeutic drug currently [ 34 , 35 ]. A drug screening study of TNBC showed that IVM could be used as a SIN3-interaction domain (SID) mimic to selectively block the interaction between SID and paired a-helix2.…”

Section: The Role Of Ivm In Different Cancersmentioning

confidence: 99%

Ivermectin, a potential anticancer drug derived from an antiparasitic drug

Tang

Wang

et al. 2021

Pharmacological Research

View full text Add to dashboard Cite

Graphical abstract Ivermectin has powerful antitumor effects, including the inhibition of proliferation, metastasis, and angiogenic activity, in a variety of cancer cells. This may be related to the regulation of multiple signaling pathways by ivermectin through PAK1 kinase. On the other hand, ivermectin promotes programmed cancer cell death, including apoptosis, autophagy and pyroptosis. Ivermectin induces apoptosis and autophagy is mutually regulated. Interestingly, ivermectin can also inhibit tumor stem cells and reverse multidrug resistance and exerts the optimal effect when used in combination with other chemotherapy drugs.

show abstract

Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer

Cited by 392 publications

References 231 publications

Exosomal miRNAs in tumor microenvironment

Exosomal miRNAs in tumor microenvironment

Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges

Ivermectin, a potential anticancer drug derived from an antiparasitic drug

Contact Info

Product

Resources

About